Taiwan Clinical Practice Guidelines for Myasthenia Gravis

Area of Science:

• Neurology
• Immunology
• Clinical Practice Guidelines

Background:

• Myasthenia gravis (MG) is an autoimmune neuromuscular disorder causing muscle weakness.
• Taiwan has experienced a rise in MG cases, particularly generalized MG (GMG), leading to increased healthcare costs.
• Standardized management protocols are needed to address the growing burden of MG.

Purpose of the Study:

• To develop evidence-based clinical guidelines for the diagnosis and management of myasthenia gravis in Taiwan.
• To standardize care across various MG subtypes and patient populations.
• To improve patient outcomes and guide future research and pharmaceutical development.

Main Methods:

• A 37-member expert committee and a patient representative were assembled.
• Systematic literature review from 2015-2024 was conducted.
• A Modified Delphi method was used to achieve consensus on clinical guidance statements.

Main Results:

• Recommendations encompass diagnosis (antibody testing, electrophysiological tests), treatment (thymectomy, steroids, biologics), and management of specific MG subtypes.
• Guidelines address ocular, early/late-onset, muscle-specific tyrosine kinase-related, refractory MG, myasthenic crisis, and neonatal MG.
• Emphasis is placed on early diagnosis, comorbidity management, and long-term care strategies.

Conclusions:

• The developed guidelines provide a standardized framework for MG management in Taiwan.
• These recommendations aim to enhance the quality of care and improve patient outcomes.
• The guidelines will serve as a foundation for future research and pharmaceutical innovation in the field.